Two-year findings from the REAL4 trial support a switch from daily growth hormone to a weekly dose of the long-acting derivative somapacitan for prepubertal children with GH deficiency.
Multifocal disease does not predict a poor outcome in children and adolescents with papillary thyroid cancer, suggest study findings from the Memorial Sloan Kettering Cancer Center in New York, USA.
Research shows that growth hormone stimulation testing failure is more common in children with short stature or impaired linear growth who also have a diagnosis of attention deficit hyperactivity disorder.
Women diagnosed with non-classical congenital adrenal hyperplasia during childhood or adolescence do not typically reach their target height, but this is not related to glucocorticoid treatment duration and dose, research shows.
Genetic variations in genes regulating the growth plate appear to play a “central role” in the aetiology of persistent short stature among children born small for gestational age, report researchers from the Czech Republic.
Researchers have identified two naturally occurring, dominant-negative variants in the growth hormone receptor gene that act via the same molecular mechanism and contribute to the nonclassical growth hormone insensitivity phenotype.
This is the 9th IMAGE programme, which focuses on transgender management, bone health, and the genetics and treatment of growth disorders.
Observational data confirm that children born small for gestational age achieve the best growth outcomes if they start treatment with recombinant human growth hormone as young as possible.
Professor Martin Savage discusses the roles of clinical, endocrinological and genetic testing in the diagnosis and care of children with idiopathic short stature.
A multigene sequencing panel has successfully identified one or more gene variants in up to one in six children with idiopathic short stature, researchers report in Endocrine Connections.
